Skip to main content
SpringerLink
Log in

Pre-treatment NS5A testing cost effective in HCV therapy

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was sponsored by Janssen-Cilag SpA, Italy.

Reference

  • Westerhout KY, et al. Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service. ClinicoEconomics and Outcomes Research : 27 Feb 2017. Available from: URL: https://doi.org/10.2147/CEOR.S117650

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pre-treatment NS5A testing cost effective in HCV therapy. PharmacoEcon Outcomes News 773, 30 (2017). https://doi.org/10.1007/s40274-017-3815-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3815-0

Search

Navigation